

**'Investing in Medical Nanotechnologies'**  
**13<sup>th</sup>-14<sup>th</sup> December 2006 – The Royal Garden Hotel, London**

---

**13<sup>th</sup> December 2006: Day 1**

08.30 – 09.20 Registration

**Session 1: The Promise of Nanomedicine I**

Chair – *Ottilia Saxl, The Institute of Nanotechnology*

09.20 – 09.30 Welcome and Introduction

09.30 – 10.00 **Keynote presentation: 'Title tbc'**

*Professor Sir Michael Rawlins, National Institute of Clinical Excellence*

10.05 – 10.35 **Keynote presentation: 'Nanomedicine: Opportunities and Roadblocks'**

*Dr Paul Smit, Philips Medical Systems*

10.40 – 11.10 **Keynote presentation: 'Nanotechnology Enabled Medicine'**

*Dr Arne Hengerer, Siemens Medical Solutions*

11.15 – 11.45 Refreshments

**Session 2: Small Company Presentations**

Chair – *Dr. Paul Smit, Philips Medical Systems*

11.45 - 11.55 **'Nanobiotechnology at the Interface'**

*Dr Dale Athey, Orla Protein Technologies Ltd*

12.00 – 12.10 **'Functional Nanocoatings for Surface Biotechnology'**

*Dr Jas Pal Badyal, Surface Innovations Technology*

12.15 – 12.25 **'Future Non-Biofouling Materials by Nanoscale Surface Modification'**

*Dr Tessa ten Cate, TNO Science and Industry*

12.30 - 12.40 **'Carbon Coated Nanomagnets for Biomedical Applications'**

*Dr Rüdiger Klingeler, Institute for Solid State Research at IFW Dresden*

12.45 - 12.55 **'Anti-cancer Therapy Using Novel Gene Delivery Technology'**

*Dr Andreas Schatzlein, Nanomerics*

13.00 – 13.55 Lunch

### **Session 3: Small Company Presentations**

Chair: *Dr Leonard Fass, GE Healthcare*

- 14.00 - 14.10      **Label-free Screening of Bio-molecular Interactions'**  
*Dr Matthew Cooper, Akubio Ltd*
- 14.15 - 14.25      **'Neuronal Regeneration using Nanotope Technology'**  
*Dr Chris Anzalone, Nanotope*
- 14.30 - 14.40      **'Nanomedicine and Infectious Diseases: The Use of Nanoviricides™ in the Treatment of Acute and Chronic Viral Illnesses'**  
*Dr Eugene Seymour, Nanoviricides Inc*
- 14.45 - 14.55      **'Selective Nanoparticle Mediated Cell Killing'**  
*Dr Martin Roland Jensen, Nannovation Biotech*
- 15.00 - 15.30      Refreshments

### **Session 4: Medical Nanotechnology – Patents, Regulation, Risks, Safety and Society**

Chair: *Ottilia Saxl, The Institute of Nanotechnology*

- 15.30 - 15.50      **Keynote Presentation: 'Nanotechnology and Risk: Insurability Challenges and Requirements for Success'**  
*Dr Thomas K Epprecht, Swiss Reinsurance Company*
- 15.55 - 16.15      **'An Introduction to Patents in Nanotechnology'**  
*Mr Hilton Lord, Marks & Clerk*
- 16.20 - 16.30      **'EMA's Reflection on Nanotechnology-based Medicinal Products for Human Use'**  
*Dr Marisa Papaluca Amati, European Medicines Agency (EMA)*
- 16.35 - 16.45      **'Lead Aerosol Size Distribution and Occupational Health'**  
*Dr Robert Muir, Innospan*
- 16.50 - 17.45      **Panel Discussion: Medical Nanotechnology – Patents, Regulation, Risks, Safety and Society**  
Panel: *Dr Thomas Epprecht, Swiss Reinsurance Company; Dr Marisa Papaluca Amati, EMA; Mr Hilton Lord, Marks & Clerk; Dr Robert Muir, Innospan*
- 17.45 - 17.50      Closing Remarks
- 17.50 - 19.00      Networking opportunity
- 19.00 - 22.30      Event Dinner

## 14<sup>th</sup> December 2006: Day 2

08.30 – 09.00 Registration

### Session 5: The Promise of Nanomedicine II

Chair – *Professor Shervanthi Homer-Vanniasinkam, Leeds Vascular Institute, The General Infirmary at Leeds*

09.00 – 09.05 Welcome

09.05 – 09.35 **Keynote Presentation: 'The Role of Nanotechnology in Healthcare'**

*Dr Leonard Fass, GE Healthcare*

09.40 – 10.10 **Keynote Presentation: 'Title tbc'**

*Dr Philippe Cleuziat, Biomerieux*

10.15 – 10.30 **'Clinical Applications of Nanobiotechnology: Possibilities and Promises'**

*Professor Shervanthi Homer-Vanniasinkam, Leeds Vascular Institute, The General Infirmary at Leeds*

10.35 – 11.00 Refreshments

### Session 6: Small Company Presentations

Chair – *Dr. Robert Porter, NPL Biotech Group*

11.00 – 11.10 **'Novel Piezoelectric Film Technology for Diagnostic Applications'**

*Mr Neil Butler, Vivacta*

11.15 – 11.25 **'Electronic Nose Technology for the Early Detection of TB'**

*Dr Tim Gibson, Scensive Technologies Ltd*

11.30 – 11.40 **'Anti-viral Nanomaterial Targeted at Pandemic Viruses'**

*Dr Paul Reip, QinetiQ Nanomaterials Ltd*

11.45 – 11.55 **'Nanoplex™ Biotags: A Transformational Optical Detection Platform for Clinical and Point-Of-Care Diagnostics'**

*Dr Peter Corish, Oxonica Healthcare*

12.00 – 12.10 **'Endomagnetism: Making Magnets Work for Healthcare'**

*Professor Q A Pankhurst, London Centre for Nanotechnology*

12.15– 12.25 **Nanoparticles for the Next Generation of Rapid Tests'**

*Dr Maryam Mehrabi, University of Liverpool*

12.30– 12.40 **'Bionanotechnology in Australia'**

*Dr Bob Irving, Nanotechnology Victoria Pty Ltd.*

12.45 – 13.45 Lunch

**Session 7: Investing in Medical Nanotechnologies – Evaluation, Finances and Challenges**  
Chair – *Del Stark, European Nanotechnology Trade Alliance*

- 13.45 – 14.05      **Keynote Presentation: ‘Medical Nanotechnology: Business Models, Financing and Valuation’**  
*Dr Ogan Gurel, Aesis Research Group Plc.*
- 14.10 – 14.30      **Keynote Presentation: ‘EIB Financing of Research, Development and Innovation Projects’**  
*Dr Kim Kreilgaard, European Investment Bank*
- 14.35 – 14.45      **‘Are You Ready for Investment?’**  
*Paula Knee, Quotec Ltd.*
- 14.50 – 15.00      **‘Reputation and Investment Risk’**  
*Dr John Browne, Strategic Advantage*
- 15.05 – 15.15      **‘The Role of Technology Roadmaps in Making Investment Decisions in Nanotechnology’**  
*Dr Malcolm Wilkinson, Technology for Industry Ltd*
- 15.20 – 15.50      **Panel Discussion: Investing in Medical Nanotechnologies – Evaluation, Finances and Challenges**  
Panel: Dr Ogan Gurel, Duravest Inc.; Dr Kim Kreilgaard, EIB; Paula Knee Quotec Ltd; Dr John Browne, Strategic Advantage; Dr Malcolm Wilkinson, TFI Ltd.
- 15.50 – 16.00      Conference Close